Fluke Infections

Larvae released by freshwater snails penetrate intact skin during water contact. The worms mature in the veins, and — uniquely among human helminths — adult schistosomes live as permanently paired couples, the female held in a groove along the male’s body, for years.

The disease is caused not by the worms but by the immune reaction to their eggs, which lodge in tissue and drive granuloma formation and fibrosis.

• S. mansoni and S. japonicum deposit eggs around the intestine and liver. Chronic infection produces Symmers’ periportal fibrosis, portal hypertension, splenomegaly and oesophageal varices — hepatosplenic schistosomiasis, where variceal haemorrhage is the major cause of death.
• S. haematobium targets the veins of the bladder and genital tract, causing haematuria, bladder-wall fibrosis, obstructive uropathy and female genital schistosomiasis. It is an IARC Group 1 carcinogen for bladder cancer.
• S. mekongi and S. intercalatum are focal and involve small numbers.

Around 140 million people are infected with S. mansoni alone, including some 35 million women of reproductive age. Praziquantel 40 mg/kg as a single dose is the treatment and the basis of school-based mass drug administration. S. japonicum is a zoonosis with an animal reservoir, which is why China’s elimination programme needed livestock control alongside treatment.

Clonorchis sinensis (15–35 million infected across China, Korea, Vietnam and the Russian Far East) and Opisthorchis viverrini (around 10 million in Thailand, Laos and Cambodia) are acquired by eating raw or fermented freshwater fish — a deeply embedded culinary practice in the endemic regions. The adult worms live in the bile ducts, where decades of mechanical irritation, chronic inflammation and oxidative DNA damage produce periductal fibrosis.

Both are IARC Group 1 human carcinogens, causing cholangiocarcinoma — bile-duct cancer. Northeast Thailand has among the highest cholangiocarcinoma rates in the world for exactly this reason. Chronic liver-fluke infection is an oncological risk that needs clearing, not a nuisance to be managed with a bitter tonic. Praziquantel cures it.

Opisthorchis felineus occupies the same niche across Eastern Europe, Russia and Siberia.

Fasciola hepatica and F. gigantica are different: acquired from aquatic plants such as watercress rather than fish, with an estimated 2.4–17 million human infections concentrated in the Andes, the Nile Delta and Iran. Migrating juveniles burrow through liver parenchyma, causing fever and pain, before settling in the bile ducts.

Praziquantel does not work well against Fasciola. Triclabendazole is the drug of choice. Emerging triclabendazole resistance is the unmet need in this group — and nothing with human data addresses it.

Paragonimus westermani and relatives are acquired from raw or undercooked freshwater crab and crayfish. The worms migrate to the lungs, causing chronic cough, haemoptysis and chest symptoms that are routinely misdiagnosed as tuberculosis — with the two co-endemic across much of Asia. Ectopic migration to the brain is the serious complication. Praziquantel cures it.

Fasciolopsis buski, the giant intestinal fluke, comes from raw aquatic plants such as water caltrop. Infection is usually mild or asymptomatic, sometimes causing GI symptoms and rarely biliary disease. It is the organism at the root of the modern parasite-cleanse industry: Hulda Clark’s claim that F. buski causes all cancers. It does not. It is a large intestinal fluke that praziquantel cures. More on the parasite-cleanse claims.

Heterophyes and Metagonimus are minute intestinal flukes from raw fish, usually causing mild GI symptoms.

Human fluke disease is not a field with a therapeutic gap for herbs to fill. Praziquantel is a cheap, single-dose oral cure for every human schistosome and for the liver, lung and intestinal flukes; triclabendazole — not praziquantel — is the drug of choice for Fasciola, a common and consequential error.

The one plant-derived success is a drug, artemisinin, not a herb.

The Mirazid Collapse

Mirazid is a proprietary petroleum-ether extract of myrrh oleo-gum-resin (Commiphora molmol), marketed in Egypt from 2001 for schistosomiasis and fascioliasis. The initial reports were spectacular. An uncontrolled series of 204 patients reported 91.7% cure after one course and 98.1% after retreatment ^{1Reference 1Sheir et al. · 2001A safe, effective herbal antischistosomal therapy derived from myrrh — uncontrolled series, n=204}. A field study in El-Fayoum reported 97.4% cure for S. haematobium and 96.2% for S. mansoni ^{2Reference 2Abo-Madyan et al. · 2004Efficacy of myrrh (Mirazid) in treating schistosomiasis in El-Fayoum — uncontrolled field study}. Neither had a praziquantel comparator arm.

Then independent groups ran it against the benchmark.

• A randomised comparison in Egyptian S. mansoni patients found Mirazid cured 15.6%, then 8.9% on retreatment, against praziquantel’s 73.7% and 76.3%; egg-reduction rates were 17–28% versus 84–88% ^{3Reference 3Barakat et al. · 2005RCTEfficacy of myrrh in the treatment of human schistosomiasis mansoni — randomized comparison with praziquantel}.
• A second controlled trial found Mirazid ~9% against praziquantel’s 62.5–79.7% ^{4Reference 4Botros et al. · 2005Efficacy of myrrh in the treatment of schistosomiasis mansoni — controlled trial versus praziquantel}.
• A third independent trial reproduced the failure ^{5Reference 5Osman et al. · 2011Evaluation of myrrh (Mirazid) versus praziquantel in schistosomiasis mansoni}.

The fascioliasis strand collapsed the same way. Uncontrolled Egyptian reports claimed 88–94% cure ^{6Reference 6Abo-Madyan et al. · 2004Mirazid in the treatment of human fascioliasis — uncontrolled field study7Reference 7Soliman et al. · 2004Mirazid in children with fascioliasis and schistosomiasis — small uncontrolled series}. A controlled ovine model — the manufacturer’s own regimen, with triclabendazole as a positive control — found Mirazid’s fluke burden just 6% below untreated animals, statistically indistinguishable from no treatment, while triclabendazole cleared every fluke ^{8Reference 8Botros et al. · 2009Trial of Mirazid in a controlled ovine fascioliasis model versus triclabendazole — Mirazid statistically indistinguishable from no treatment}.

A defence review argued the critics had under-dosed ^{9Reference 9Yakoot · 2010ReviewA short review of the anthelmintic role of Mirazid — defence of the preparation}. The definitive controlled trial used the manufacturer’s own regimen.

The failure has a recognisable shape: uncontrolled series in an endemic population, no comparator, a marketed product, and cure rates that evaporated the moment somebody put a proven drug in the other arm. The pattern recurs across botanical antiparasitics, and Mirazid is its cleanest documented instance.

Artemisinin — A Drug Story, And Why WHO Says No Anyway

The isolated drugs work because they reach a stage praziquantel misses: praziquantel kills adult worms but spares the 2–3 week juvenile schistosomula. Artemisinin derivatives kill the juveniles. Two drugs, two stages.

As prophylaxis the data are strong. In a double-blind placebo-controlled trial at Poyang Lake, 783 people were given a curative praziquantel dose and then artemether or placebo every two weeks: new patent infection appeared in 3/373 (0.8%) on artemether against 56/361 (15.0%) on placebo, with geometric-mean intensity falling 96.1% against a 50.8% rise ^{10Reference 10Li et al. · 2005RCTDouble-blind randomised trial of artemether prophylaxis against Schistosoma japonicum, Poyang Lake — incidence 0.8% vs 15.0% placebo}. A trial in Côte d’Ivoire reproduced the effect against S. haematobium ^{11Reference 11N’Goran et al. · 2003RCTRandomised placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections}. This is the basis of the Chinese schistosomiasis-japonica programme ^{12Reference 12Xiao et al. · 2000ReviewArtemether as a prophylactic against schistosomiasis japonica — review of Chinese laboratory and field trials}.

As treatment the picture is the opposite. Artesunate monotherapy is reproducibly inferior to praziquantel — a meta-analysis found praziquantel’s cure rate 1.66 times artesunate’s, and artesunate not clearly better than placebo ^{13Reference 13Wikman-Jorgensen et al. · 2012Meta-analysisArtesunate versus praziquantel for urinary schistosomiasis — systematic review and meta-analysis; praziquantel cure RR 1.66}; a double-blind RCT in 800 Malian children gave artesunate-plus-sulfamethoxypyrazine 43.9% cure against praziquantel’s 53.0% ^{14Reference 14Sissoko et al. · 2009RCTDouble-blind RCT of artesunate + sulfamethoxypyrazine versus praziquantel for S. haematobium in 800 Malian children}. Adding an artemisinin to praziquantel does raise cure modestly in meta-analysis ^{15Reference 15Pérez del Villar et al. · 2012Meta-analysisSystematic review and meta-analysis of artemisinin-based therapies for schistosomiasis — monotherapy inferior, combination superior to praziquantel alone16Reference 16Yang et al. · 2026Meta-analysisMeta-analysis of praziquantel plus artemisinin derivatives versus praziquantel monotherapy — authors flag artemisinin-resistance risk in co-endemic regions}, but the absolute gain is small and praziquantel alone already cures most people far more cheaply.

WHO’s objection is stewardship. Deploying artemisinins for schistosomiasis in malaria-endemic areas risks selecting for artemisinin resistance in Plasmodium falciparum — the one drug class malaria control cannot afford to lose. The same argument governs the Artemisia annua debate in malaria, and it is flagged even by the 2026 meta-analysis that favours the combination ^{16Reference 16Yang et al. · 2026Meta-analysisMeta-analysis of praziquantel plus artemisinin derivatives versus praziquantel monotherapy — authors flag artemisinin-resistance risk in co-endemic regions}.

The flagship whole-herb trial — Artemisia annua and A. afra tea infusions against schistosomiasis — was retracted ^{17Reference 17Retraction notice · 2020Clinical trialfor Munyangi et al., Phytomedicine 2018 — “Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial”}, alongside the same group’s malaria trial. There is no valid human evidence that the whole herb treats schistosomiasis. Artemisinin is not Artemisia annua.

Snail Control — Where Plants Contributed

Killing the snail is not treating the person. It is the most conflated distinction in the field.

Phytolacca dodecandra — endod, the African soapberry — is the best-evidenced plant molluscicide there is. Its oleanane saponins (lemmatoxin, oleanoglycotoxin-A) lyse snail cell membranes at an LC50 of about 6.8–9.6 mg/L, and they biodegrade within a few days ^{18Reference 18Mølgaard et al. · 2000Biodegradability and molluscicidal potency of endod saponins — LC50 6.8–9.6 mg/L against Biomphalaria}. In a five-year community control trial in Adwa, Ethiopia, S. mansoni prevalence fell from 61.5% to 36.4% in the endod area, performing comparably to synthetic niclosamide at roughly six US cents per person per year ^{19Reference 19Goll et al. · 1983Control of schistosomiasis in Adwa, Ethiopia, using the plant molluscicide endod — five-year community trial}. Later fieldwork achieved up to 100% snail mortality using a spray method ^{20Reference 20Abebe et al. · 2005Field application of endod spray versus powder-soap against schistosomiasis vector snails, Ethiopia}. It was discovered by the Ethiopian scientist Aklilu Lemma.

It never displaced niclosamide at programme scale — cost, standardisation, the sheer quantity of plant material required, and aquatic non-target toxicity all told against it, and like all snail control the benefit erodes without sustained reapplication.

Ambrosia maritima (damsissa) kills snails, but the effect does not last. Field trials in the Senegal River basin reduced Bulinus by 54–56% and Biomphalaria by up to 77% at two weeks — followed by rapid recolonisation ^{21Reference 21Belot et al. · 1993Field trials of Ambrosia maritima against schistosomiasis vector snails in the Senegal River basin}. A seven-year epidemiological trial across four Nile Delta villages found no consistent durable transmission benefit attributable to it beyond chemotherapy ^{22Reference 22Barakat et al. · 1993ObservationalSeven-year epidemiological trial of Ambrosia maritima in Nile Delta villages — no consistent durable transmission benefit}.

A broader class of saponin-bearing plants is molluscicidal at low parts-per-million — Dracaena fragrans at an LC50 around 2–2.7 ppm ^{23Reference 23Tadros et al. · 2008Steroidal saponin fraction of Dracaena fragrans against Biomphalaria alexandrina and Bulinus truncatus — LC50 2.0–2.7 ppm}, and a tea-seed distilled saponin now field-tested in China against all three major vector snails ^{24Reference 24Jia et al. · 2019Tea-seed distilled saponin molluscicide (“Luo-Wei”) against Oncomelania, Biomphalaria and Bulinus — laboratory, field and non-target toxicity}. All carry the same constraint: toxic to fish, birds and crustaceans at effective concentrations.

None of these is a human therapy. All are prevention.

Direct Antischistosomal Botanicals — And Why They Fail

Adult schistosomes live in the mesenteric and vesical veins. That is a bloodstream target, so the gut-lumen contact argument that makes an oral anthelmintic plausible against a tapeworm does not apply to them. An in-vitro killing concentration is only meaningful if it is achievable in plasma.

Ethyl-acetate ginger extract at 200 mg/L killed nearly all adult S. mansoni within 24 hours in vitro. In the same study, 150 mg/kg given orally or subcutaneously to infected mice produced no significant worm reduction at all ^{25Reference 25Sanderson et al. · 2002In vitroIn vitro and in vivo studies on the bioactivity of a ginger (Zingiber officinale) extract towards adult schistosomes and their egg production — potent in vitro, no in-vivo worm reduction}. Potent in a dish, zero in the animal. Later mouse work reports reductions ^{26Reference 26Mostafa et al. · 2011AnimalAntischistosomal activity of aqueous ginger extract in S. mansoni-infected mice}, so the literature is mixed, but the same-study null shows the gap between dish and animal.

Nigella seed and oil kill S. mansoni at all stages in vitro and lower worm burden and hepatic egg deposition in mice, apparently by suppressing the worm’s own antioxidant enzymes (SOD, glutathione peroxidase and reductase) and glucose-metabolism enzymes so host oxidants can finish it ^{27Reference 27Mohamed et al. · 2005In vitroNigella sativa seeds against Schistosoma mansoni stages and antioxidant-enzyme activity in vitro28Reference 28Ali et al. · 2016AnimalOral Nigella sativa oil in S. mansoni-infected mice — worm burden and hepatic egg reduction}. There are no human data.

Turmeric is bioavailability-limited: free curcumin reduced worm and egg burden about 45% in mice, while curcumin-gold-nanoparticles plus praziquantel reached 97.4% ^{29Reference 29Mokbel et al. · 2020AnimalCurcumin versus curcumin-gold nanoparticles ± praziquantel in S. mansoni-infected mice}. The gap between those two numbers is the bioavailability problem. Nanoformulated curcumin is not turmeric.

Garlic oil is strongly cercaricidal — 100% cercarial mortality at 10⁻⁶ v/v within 30 minutes, with pre-exposure application preventing infection in mice ^{30Reference 30Wan et al. · 2017In vitroCercaricidal and preventive efficacy of garlic oil against Schistosoma japonicum in vitro and in mice}. That is killing the larva before it penetrates skin: a prevention property, not a treatment for an established infection.

The Liver-Fluke Gap

There is no human trial of any botanical against Clonorchis, Opisthorchis, Paragonimus or Fasciola.

What exists is in-vitro worm-killing — Thunbergia laurifolia against O. viverrini juveniles and adults ^{31Reference 31Pechdee et al. · 2025In vitroThunbergia laurifolia crude extract against Opisthorchis viverrini newly excysted juveniles and adults in vitro}, garlic extract against adult O. viverrini with oxidative-stress markers ^{32Reference 32Pechdee et al. · 2024In vitroAllium sativum crude extract against adult Opisthorchis viverrini in vitro — worm death with oxidative-stress markers} — and hamster work on the host side: T. laurifolia given after praziquantel reduced inflammation and inhibited cholangiocarcinoma development ^{33Reference 33Wonkchalee et al. · 2013Thunbergia laurifolia after praziquantel in the O. viverrini hamster cholangiocarcinoma model — reduced inflammation and inhibited CCA development}, and an anthocyanin-plus-turmeric complex reduced periductal fibrosis and oxidative DNA damage ^{34Reference 34Intuyod et al. · 2014Anthocyanin complex in O. viverrini-infected hamsters — reduced periductal fibrosis and 8-oxodG}.

The host-side work points to a role as an adjunct after cure, since fibrosis and cancer risk persist beyond parasite clearance. It is no substitute for clearing the infection. These are Group 1 carcinogens. The imperative is cure.

The anti-Fasciola literature is in-vitro and veterinary — thymoquinone and curcumin reducing fluke motility modestly ^{35Reference 35Ullah et al. · 2017In vitroThymoquinone and curcumin against adult Fasciola gigantica in vitro — modest motility reduction}, Momordica charantia blocking egg development ^{36Reference 36Pereira et al. · 2016In vitroMomordica charantia leaf extract against Fasciola hepatica eggs in vitro (veterinary)}, a 20-plant screen against newly excysted flukes ^{37Reference 37Vera-Montenegro et al. · 2008In-vitro screen of 20 plant extracts against newly excysted Fasciola hepatica (veterinary)}. No human trial, and the real problem — triclabendazole resistance — is untouched.

Host Support, And A Specific Danger

Milk thistle is the most plausible host-support adjunct in schistosomiasis, and its data are still mouse-only. Silymarin reduced hepatic granuloma size and TGF-β1-driven fibrosis in S. mansoni-infected mice, best in combination with praziquantel ^{38Reference 38El-Sayed et al. · 2016AnimalSilymarin ± praziquantel in S. mansoni-infected mice — granuloma size and cytokine modulation39Reference 39El-Hawary et al. · 2018AnimalComplementary Effect of Capparis Spinosa L. and Silymarin With/without Praziquantel on Mice Experimentally Infected with Schistosoma Mansoni40Reference 40El-Nagar et al. · 2021AnimalSilymarin added to praziquantel or Mirazid in S. mansoni-infected mice — fibrosis and histopathology}. There is no human trial in hepatosplenic schistosomiasis.

Hepatosplenic schistosomiasis means periportal fibrosis, portal hypertension and oesophageal varices — and variceal haemorrhage is the major cause of death. Garlic (via ajoene) ^{41Reference 41Teranishi et al. · 2003In vitroAjoene (garlic derivative) inhibits platelet aggregation in vitro and in vivo}, ginger (6-shogaol and 6-gingerol) ^{42Reference 42Ahmed et al. · 2023Antiplatelet activity of 6-gingerol derivatives — 6-shogaol the best lead}, ginkgo ^{43Reference 43Mai et al. · 2025Ginkgo biloba drug interactions and bleeding risk — retrospective analysis of 2,647 prescriptions} and high-dose fish oil ^{44Reference 44Bedi et al. · 2016Case reportPostoperative bleeding attributed to fish oil plus garlic supplements — case report} all impair platelet function; a review of twenty supplements found 45% had antiplatelet activity ^{45Reference 45Abebe · 2019ReviewReview of herbal medications with bleeding potential — 45% of 20 reviewed supplements antiplatelet}.

The effect sizes are modest and much of the data is in-vitro or case-level. In a patient with varices, the downside is not modest. Garlic and ginger are also weak antischistosomal candidates, and the bleeding flag travels with them.

Praziquantel interactions. Praziquantel undergoes heavy CYP3A4 first-pass metabolism. Strong inducers slash it: rifampicin reduced plasma praziquantel to undetectable in several volunteers ^{46Reference 46Ridtitid et al. · 2002Rifampicin markedly decreases plasma praziquantel concentrations in healthy volunteers}, and phenytoin and carbamazepine markedly reduced its bioavailability ^{47Reference 47Bittencourt et al. · 1992Phenytoin and carbamazepine decrease praziquantel bioavailability in neurocysticercosis}. The CYP3A4 inhibitor ketoconazole raises exposure ^{48Reference 48Ridtitid et al. · 2007RCTKetoconazole increases praziquantel plasma concentrations — randomized crossover pharmacokinetic study}. St John’s wort is a well-established CYP3A4 inducer, so the concern with it is mechanistically expected rather than directly measured — no St John’s wort × praziquantel study exists. Screen for inducers before treatment; subtherapeutic praziquantel means the fluke survives.